Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Amortizatization of Intangibles (2019 - 2025)

BridgeBio Pharma's Amortizatization of Intangibles history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 47.23% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $4.9 million, up 19.27%, while the annual FY2025 figure was $4.9 million, 19.27% up from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $1.5 million at BridgeBio Pharma, up from -$49.7 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $27.5 million in Q2 2025 and bottomed at -$49.7 million in Q3 2025.
  • The 5-year median for Amortizatization of Intangibles is $1.8 million (2021), against an average of $1.4 million.
  • The largest YoY upside for Amortizatization of Intangibles was 1546.58% in 2025 against a maximum downside of 8705.5% in 2025.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $1.8 million in 2021, then rose by 19.92% to $2.1 million in 2022, then plummeted by 228.13% to -$2.7 million in 2023, then skyrocketed by 136.81% to $991000.0 in 2024, then soared by 47.23% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Amortizatization of Intangibles are $1.5 million (Q4 2025), -$49.7 million (Q3 2025), and $27.5 million (Q2 2025).